Close menu

SURE

Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Socio-demographic disparities in HER2+ breast cancer trastuzumab receipt: An English population-based study.

Norris, Ruth P, Dew, Rosie, Greystoke, Alastair, Cresti, Nicola, Cain, Henry, Todd, Adam and Sharp, Linda (2024) Socio-demographic disparities in HER2+ breast cancer trastuzumab receipt: An English population-based study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. ISSN 1538-7755

Item Type: Article

Abstract

BACKGROUND

Socio-demographic disparities in traditional breast cancer treatment receipt in non-publicly funded healthcare systems are well documented. This study investigated trastuzumab receipt by socio-demographic factors within a female, HER2+ breast cancer population in England's publicly funded National Health Service.

METHODS

The English national population-based cancer registry and linked Systemic Anti-Cancer Therapy (SACT) database identified 36,985 women with HER2+ invasive breast cancer diagnosed 01/01/2012-31/12/2017. Multivariable logistic regression determined likelihood of trastuzumab receipt in (i) early and (ii) metastatic disease by deprivation category of area of residence and other socio-demographic characteristics.

RESULTS

Early-stage trastuzumab receipt followed a socio-economic gradient. Women residing in the most deprived areas were 10% less likely to receive trastuzumab (multivariable OR 0.90, (95% CI) 0.83, 0.98) compared to women residing in the least deprived areas. In both early and metastatic disease, trastuzumab receipt was less likely in older women with more comorbidities, ER positive disease, and who were not discussed at a multidisciplinary team meeting.

CONCLUSIONS

Despite provision of free at the point of delivery care in England, socio-demographic disparities in early-stage HER2+ trastuzumab receipt occur. Further research determining how inequities contribute to disparities in outcomes is warranted to ensure optimized trastuzumab use for all.

IMPACT

Fair access to novel cancer treatments regardless of place of residence, socio-demographic characteristics, and/or cancer stage requires prioritization in future cancer improvement policies.

[img]
Preview
PDF
epi-24-0144.pdf
Available under License Creative Commons Attribution.

Download (1MB) | Preview

More Information

Related URLs:
Depositing User: Rosie Dew

Identifiers

Item ID: 18289
Identification Number: https://doi.org/10.1158/1055-9965.EPI-24-0144
ISSN: 1538-7755
URI: http://sure.sunderland.ac.uk/id/eprint/18289
Official URL: https://doi.org/10.1158/1055-9965.EPI-24-0144

Users with ORCIDS

Catalogue record

Date Deposited: 26 Sep 2024 09:47
Last Modified: 26 Sep 2024 09:47

Contributors

Author: Ruth P Norris
Author: Rosie Dew
Author: Alastair Greystoke
Author: Nicola Cresti
Author: Henry Cain
Author: Adam Todd
Author: Linda Sharp

Subjects

Sciences > Health Sciences

Actions (login required)

View Item (Repository Staff Only) View Item (Repository Staff Only)